Oncotarget

Research Papers:

Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic

Kenneth Oguejiofor, Henry Galletta-Williams, Simon J. Dovedi, Darren L. Roberts, Peter L. Stern _ and Catharine M.L. West

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:14416-14427. https://doi.org/10.18632/oncotarget.14796

Metrics: PDF 2176 views  |   HTML 3054 views  |   ?  


Abstract

Kenneth Oguejiofor1, Henry Galletta-Williams1, Simon J. Dovedi2, Darren L. Roberts1, Peter L. Stern3 and Catharine M.L. West1

1 Translational Radiobiology Group, Division of Molecular & Clinical Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Christie Hospital NHS Trust, Manchester, UK

2 Targeted Therapy Group, Division of Molecular & Clinical Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Christie Hospital NHS Trust, Manchester, UK

3 Immunology/Children’s Cancer Group, Division of Molecular & Clinical Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Christie Hospital NHS Trust, Manchester, UK

Correspondence to:

Peter L. Stern, email:

Keywords: checkpoint inhibitor, PD-L1, human papillomavirus, oropharyngeal squamous cell carcinomas, tumour infiltrating lymphocytes

Received: January 10, 2017 Accepted: January 11, 2017 Published: January 22, 2017

Abstract

Immunotherapies are beginning to revolutionise treatment paradigms in oncology with monoclonal antibodies (mAb) targeting T-cell co-inhibitory (e.g. PD-1/PD-L1) and co-stimulatory pathways (e.g. CTLA-4/CD28) demonstrating clinical utility. Some clinical studies demonstrate that responsiveness to PD-1/PD-L1 mAb therapy is greater in patients with expression of PD-L1 in the tumour microenvironment. However, robust responses have also been observed in patients with low or absent expression of PD-L1. Using multiplex immuno-fluorescent labelling we sought to determine how infiltration of tumours by CD8+ T-cells, their expression of PD-1, and the expression of PD-L1 on both tumours and CD68 cells (macrophages) correlated with HPV status and outcome in a cohort of 124 oropharyngeal squamous cell carcinomas (OPSCC).


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14796